Avalo CMO exercises options, sells 679 shares

Avalo Therapeutics, Inc. (AVTX) reported that Chief Medical Officer Mittie Doyle exercised stock options for 679 shares of common stock at an exercise price of $8.04 per share and on the same day sold 679 shares of common stock at $20.00 per share.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. (AVTX) reported that Chief Medical Officer Mittie Doyle exercised stock options for 679 shares of common stock at an exercise price of $8.04 per share and on the same day sold 679 shares of common stock at $20.00 per share. After the option exercise, Doyle held 113,734 stock options directly. All transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025, and the underlying option grant vests 25% on January 28, 2026, with the remainder vesting in equal monthly installments over the following three years.

Insider Trade Summary 10b5-1

Exercise and Sale: 679 shares ($8K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Doyle Mittie

Role Chief Medical Officer

Sold 679 shs ($14K)

Approx. gross sale proceeds $14K

Approx. exercise cost $5K

Approx. pre-tax spread $8K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F2	679	$0.00	$0.00
Exercise	Common Stock F1	679	$8.04	$5K
Sale	Common Stock F1	679	$20.00	$14K

Holdings After Transaction: Stock Option (Right to Buy) — 113,734 contracts (Direct); Common Stock — 51,776 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
2. F2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Options exercised: 679 shares Option exercise price: $8.04 per share Shares sold: 679 shares +4 more

7 metrics

Options exercised 679 shares Stock Option (Right to Buy) exercised on August 28, 2026

Option exercise price $8.04 per share Exercise or conversion of derivative security into common stock

Shares sold 679 shares Sale of common stock on August 28, 2026

Sale price $20.00 per share Sale of 679 shares of common stock

Stock options outstanding after transaction 113,734 options Total stock options following the reported derivative transaction

Option expiration date January 28, 2035 Expiration of the stock option relating to the exercised shares

Initial vesting portion 25% Vests on January 28, 2026, with remaining vesting monthly over three years

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), Exercise or conversion of derivative security, vesting, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

vesting financial

"The stock option vests twenty-five percent (25%) on January 28, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2035-01-28""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AVTX Chief Medical Officer Mittie Doyle report?

Mittie Doyle reported exercising stock options for 679 shares of Avalo Therapeutics common stock at $8.04 per share and selling 679 shares of common stock at $20.00 per share on August 28, 2026, in transactions reported on Form 4.

Was the AVTX insider trading activity under a Rule 10b5-1 plan?

Yes. The Form 4 states that all reported transactions were effected under a Rule 10b5-1 trading plan adopted by Mittie Doyle on November 13, 2025, indicating the trades were made pursuant to a pre-arranged plan.

What stock option terms apply to Mittie Doyle’s AVTX grant?

The stock option referenced vests 25% on January 28, 2026, with the remaining portion vesting in equal monthly installments over three years, subject to Doyle’s continued service on each vesting date. The option has an exercise price of $8.04 per share and expires on January 28, 2035.

How many AVTX stock options does Mittie Doyle hold after these transactions?

Following the reported option exercise, Mittie Doyle directly held 113,734 stock options of Avalo Therapeutics, according to the Form 4 derivative holdings field tied to the exercised option.

What prices were involved in the AVTX insider’s exercise and sale?

The Form 4 shows an option exercise price of $8.04 per share for 679 shares of common stock and a sale price of $20.00 per share for 679 shares of common stock, both dated August 28, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:39 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle Mittie

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/28/2026		M(1)		679	A	$8.04	52,455	D
Common Stock	08/28/2026		S(1)		679	D	$20	51,776	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.04	08/28/2026		M(1)			679	(2)	01/28/2035	Common Stock	679	$0	113,734	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.

2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher Sullivan, Attorney-in-Fact	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)